Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With Resectable, High-Risk Cutaneous Squamous Cell Carcinoma

NCT07100925 is registered in ClinicalTrials.gov with Ankyra Therapeutics, Inc as lead sponsor.

NCT NCT07100925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07100925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With Resectable, High-Risk Cutaneous Squamous Cell Carcinoma
Lead sponsor
Ankyra Therapeutics, Inc
Phase
Phase 1
Overall status
Withdrawn
Start date
December 15, 2025
Completion date
December 31, 2030
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous squamous cell carcinoma (cscc), renal transplant, solid tumor, solid tumor cancer